| |
Inviragen Merger Profiled
in Inc. Magazine
fort collins,
co.,
May 7, 2010
Inviragen’s recent merger with SingVax
is profiled this month in Inc. magazine, a national publication
that delivers advice, tools, and services to help business
owners and CEOs start, run, and grow their businesses more
successfully.
In September 2009, Inviragen, a U.S.-based vaccine company,
and SingVax, a Singapore-based vaccine company, merged to create
a company that is developing vaccines for infectious diseases
prevalent in emerging economies. Concurrent with the merger,
the combined company raised $15 million in a Series A equity
investment from a syndicate of international venture capital
investors.
The complexities of an international merger with multiple investors,
enormous physical distance, and the difficulties meshing leadership
and prioritizing multiple resource needs intrigued one of the
writers for Inc. and a feature story resulted. For the full
article, please see http://www.inc.com/magazine/20100501/case-study-attempting-a-global-
merger.html.
“Post-merger, we have combined our operations and are
capitalizing on the synergy created,” noted Dr. Joseph
Santangelo, Inviragen’s Chief Operating Officer. “Our
integrated international R&D capabilities position us well
to continue to translate needed vaccines from the bench to
the clinic.”
“We are pleased that now, six months after the official
merger, Inviragen is rapidly moving ahead,” commented
Dr. Dan Stinchcomb, Inviragen’s Chief Executive Officer. “We
have three vaccines poised to begin human clinical trials.
Our lead vaccine, designed to protect against dengue fever,
will begin clinical trials this quarter.”
About Inviragen
Inviragen is focused on developing life-saving vaccines to
protect against emerging infectious diseases worldwide. Inviragen's
lead product candidate is a vaccine to protect against dengue
fever, a disease that threatens 3.6 billion people across the
globe. Inviragen is also developing vaccines to protect against
hand, foot and mouth disease and Japanese encephalitis, both
of which affect millions of children in Asia. Vaccines in preclinical
research stages include a low-cost human papilloma virus vaccine,
a chikungunya vaccine, and vaccines to protect against new
forms of influenza for global health markets. Inviragen has
offices and laboratories in Fort Collins, Colorado, Madison,
Wisconsin and Singapore. Please see www.inviragen.com for more
details.
.
About Charter Life Sciences
Charter Life Sciences (“CLS”) is a life sciences venture capital
firm with offices in Palo Alto, California and Cincinnati, Ohio. CLS focuses
on providing the initial venture capital to companies that are developing innovative
products for significant unmet medical needs. The CLS team draws on its extensive
medical, operational and start-up company experience to work collaboratively
with its portfolio companies to develop their clinical, operational and financing
strategies. For additional information on CLS, please visit www.clsvc.com.
CONTACT:
Ted Rossman/Lisa Kelaita
New Venture Communications
(650) 343-2735
trossman@newventurecom.com
lkelaita@newventurecom.com
|
|
